Results
1184
Companies which are more than 50% undervalued based on analyst price target.
1,184 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
MSTR | US$334.62 | -3.6% | 366.4% | US$82.6b | US$513.01 | PS182x | E57.1% | n/a | Software | ||
ON | US$47.04 | -6.4% | -41.9% | US$21.8b | US$71.01 | PE12.7x | E13.5% | n/a | Semiconductors | ||
BIIB | US$142.54 | 0.1% | -41.8% | US$20.6b | US$222.48 | PE12.9x | E9.8% | n/a | Pharmaceuticals & Biotech | ||
EIX | US$50.17 | -4.3% | -23.3% | US$19.4b | US$81.18 | PE14.7x | E13.5% | 6.6% | Utilities | ||
FSLR | US$162.89 | -2.6% | 3.6% | US$18.0b | US$267.53 | PE14x | E24.2% | n/a | Semiconductors | ||
SMMT | US$20.50 | 2.6% | 339.0% | US$14.8b | US$33.08 | PB34.5x | E38.9% | n/a | Pharmaceuticals & Biotech | ||
MRNA | US$31.87 | -12.8% | -64.2% | US$12.5b | US$62.32 | PS2.4x | E20.0% | n/a | Pharmaceuticals & Biotech | ||
BMRN | US$63.50 | 1.7% | -28.0% | US$12.2b | US$96.86 | PE37.5x | E24.1% | n/a | Pharmaceuticals & Biotech | ||
FTAI | US$116.68 | 7.8% | 115.5% | US$11.6b | US$185.51 | PS7.7x | E53.0% | 1.0% | Capital Goods | ||
PCVX | US$85.94 | 1.3% | 12.5% | US$10.9b | US$149.89 | PB3.1x | E27.1% | n/a | Pharmaceuticals & Biotech | ||
SRPT | US$112.74 | -1.2% | -9.2% | US$10.8b | US$181.78 | PE88.4x | E30.5% | n/a | Pharmaceuticals & Biotech | ||
VFS | US$3.79 | 0% | -29.3% | US$8.9b | US$6.33 | PS6x | E0.006% | n/a | Automobiles | ||
RVMD | US$42.06 | -0.2% | 37.6% | US$7.8b | US$73.29 | PS10475.1x | E20.1% | n/a | Pharmaceuticals & Biotech | ||
ASND | US$119.49 | -4.5% | -17.4% | US$7.2b | US$193.27 | PS21.2x | E57.7% | n/a | Pharmaceuticals & Biotech | ||
LEGN | US$35.73 | -4.2% | -40.9% | US$6.5b | US$79.83 | PS12.6x | E56.5% | n/a | Pharmaceuticals & Biotech | ||
LNTH | US$86.91 | -2.9% | 53.7% | US$6.2b | US$134.69 | PE14.1x | E12.8% | n/a | Healthcare | ||
BBIO | US$31.76 | 2.4% | -10.9% | US$6.0b | US$49.49 | PS27.6x | E42.0% | n/a | Pharmaceuticals & Biotech | ||
ANF | US$113.19 | -2.0% | -1.5% | US$5.8b | US$187.40 | PE10.6x | E7.3% | 0% | Retail | ||
MARA | US$16.76 | -6.6% | -38.6% | US$5.7b | US$27.00 | PE34.6x | E-35.1% | n/a | Software | ||
CELH | US$21.68 | -8.8% | -63.4% | US$5.3b | US$37.91 | PE29.9x | E19.0% | n/a | Food, Beverage & Tobacco | ||
CYTK | US$42.21 | -12.9% | -46.8% | US$5.0b | US$79.70 | PS1547.5x | E39.6% | n/a | Pharmaceuticals & Biotech | ||
ZETA | US$21.66 | 19.1% | 113.0% | US$5.0b | US$36.92 | PS5.7x | E125.6% | n/a | Software | ||
IONS | US$31.48 | -2.0% | -37.5% | US$5.0b | US$61.32 | PS6.2x | E40.4% | n/a | Pharmaceuticals & Biotech | ||
IEP | US$9.65 | -2.0% | -50.1% | US$4.9b | US$15.00 | PS0.5x | E182.3% | 20.7% | Capital Goods |